Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-013733
Filing Date
2023-08-08
Accepted
2023-08-08 07:01:15
Documents
56
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20230630x10q.htm   iXBRL 10-Q 1603798
2 EX-31.1 tmb-20230630xex31d1.htm EX-31.1 7126
3 EX-31.2 tmb-20230630xex31d2.htm EX-31.2 7116
4 EX-32.1 tmb-20230630xex32d1.htm EX-32.1 9203
5 GRAPHIC tmb-20230630x10q001.jpg GRAPHIC 17235
  Complete submission text file 0001558370-23-013733.txt   5613179

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20230630.xsd EX-101.SCH 35444
7 EX-101.CAL tmb-20230630_cal.xml EX-101.CAL 32382
8 EX-101.DEF tmb-20230630_def.xml EX-101.DEF 119915
9 EX-101.LAB tmb-20230630_lab.xml EX-101.LAB 287797
10 EX-101.PRE tmb-20230630_pre.xml EX-101.PRE 213375
50 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230630x10q_htm.xml XML 1011739
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37410 | Film No.: 231149234
SIC: 2834 Pharmaceutical Preparations